RTP Mobile Logo
Hematologic Oncology Update, Issue 3, 2010
Released September 2010

Featuring interviews with Drs Mathias J Rummel, Antonio Palumbo, Mikkael A Sekeres and Steven T Rosen. (Text and Audio Content)

CE Disclosures and Faculty Information


    More than 45 pharmaceutical agents with more than 55 distinct FDA-approved indications are currently available for the management of the numerous types of hematologic cancer. This extensive armamentarium of therapeutic options poses a challenge to clinicians who must maintain up-to-date knowledge of optimal treatment algorithms for diverse tumor types. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of state-of-the-art clinical management strategies, which in turn facilitates optimal patient care.


    • Apply the results of emerging research to effectively integrate novel agents and regimens into the management of follicular lymphoma.
    • Recall early mortality in acute promyelocytic leukemia (APL), and formulate optimal management strategies for APL.
    • Identify patients at high risk for tumor lysis syndrome (TLS), and incorporate recent research data into the prevention and management of TLS.
    • Integrate innovative combination regimens into the management of multiple myeloma (MM), considering the benefits and risks of proteasome inhibitors and immunomodulatory agents.
    • Evaluate maintenance therapy approaches for patients with MM.
    • Optimize the management of myelodysplastic syndromes through rational integration of prospective and retrospective data.
    • Counsel appropriately selected patients about the availability of ongoing clinical trials in which they may be eligible to participate.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Prof RummelAdvisory Committee: Amgen Inc, Cephalon Inc, GlaxoSmithKline. Dr PalumboAdvisory Committee and Consulting Agreements: Amgen Inc, Celgene Corporation, Millennium Pharmaceuticals Inc, Onyx Pharmaceuticals Inc. Dr SekeresAdvisory Committee: Celgene Corporation, Seattle Genetics; Speakers Bureau: Celgene Corporation. Dr RosenClinical Trial Grants: Berlex Inc, Celgene Corporation, Wyeth; Consulting Agreements: Abbott Laboratories, Allos Therapeutics, Berlex Inc, BioCryst Pharmaceuticals Inc, Celgene Corporation, CT International, Genentech BioOncology, Genta Inc, Ligand Pharmaceuticals, Lilly USA LLC, Pharmion Corporation, Sigma-Tau Pharmaceuticals Inc, SuperGen Inc, Therakos Inc, Wyeth; Honoraria: Celgene Corporation, Genentech BioOncology, Ligand Pharmaceuticals; Speakers Bureau: Merck and Company Inc.

    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium Pharmaceuticals Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2010
    Expiration date: September 2011

Acknowledge and close

Hematologic Oncology Update, Issue 3, 2010
Released September 2010

Featuring interviews with Drs Mathias J Rummel, Antonio Palumbo, Mikkael A Sekeres and Steven T Rosen. (Text and Audio Content)